<DOC>
	<DOCNO>NCT00507741</DOCNO>
	<brief_summary>This Phase II clinical trial evaluate benefit therapy vintafolide participant advanced ovarian endometrial cancer .</brief_summary>
	<brief_title>Study Vintafolide ( MK-8109 , EC145 ) Participants With Advanced Ovarian Endometrial Cancers ( MK-8109-007 , EC-FV-02 )</brief_title>
	<detailed_description>This Phase II clinical trial vintafolide administer participant advanced ovarian endometrial cancer . Vintafolide drug specifically design enter cancer cell via folate vitamin receptor ( FR ) . Experimental evidence show target receptor express virtually ovarian cancer well majority endometrial cancer . Early clinical evidence small number Phase I patient suggest vintafolide may antitumor effect woman advance ovarian cancer generally well-tolerated . This evidence suggest vintafolide may useful chemotherapy advanced ovarian endometrial cancer . The primary objective Part A study collect data clinical benefit produce therapy vintafolide . The primary objective Part B study collect data safety efficacy vintafolide . All participant undergo image FR target investigational imaging agent ertafolide ( EC20 , FolateScan ) screen period confirm eligibility treatment portion clinical trial . Clinical evidence suggest ertafolide may use identify woman cancer express target receptor . Information safety tolerability vintafolide ertafolide assess .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>Part A : Radiographic evidence measurable disease ( Response Evaluation Criteria In Solid Tumors [ RECIST ] ) either : Advanced epithelial ovarian cancer serous endometrioid histology , confirm previous biopsy , ertafolide scan positive ovarian cancer , primary peritoneal cancer adenocarcinoma endometrium . Prior treatment platinum and/or taxane compound . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 . At least 4 week prior therapy recover associate acute toxicity . Adequate bone marrow reserve , renal , hepatic function . Negative serum pregnancy test woman childbearing potential willingness practice contraceptive method . Serious comorbidities ( determine Principal Investigator ) . Women pregnant lactating . Symptomatic central nervous system ( CNS ) metastasis . Prior radiation therapy assessable disease , unless disease progression confirm site . Requires palliative radiotherapy time study entry . Unable tolerate condition radionuclide image . Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational . Those administer another radiopharmaceutical would interfere assessment 99mTcertafolide scan . Part B : Radiographic evidence measurable disease ( RECIST criterion ) ertafolide scan positive recurrent persistent epithelial ovarian , primary fallopian tube , peritoneal cancer . Prior treatment platinum compound , 4 prior cytotoxic chemotheraputic regimen . ECOG Performance status 02 . At least 3 week prior cytotoxic therapy recover associate acute toxicity . Adequate bone marrow reserve , renal , hepatic function . Negative serum pregnancy test woman childbearing potential willingness practice contraceptive method . Serious comorbidities ( determine Principal Investigator ) . Women pregnant lactating . Symptomatic CNS metastasis . Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational . Those prior therapy Vinorelbine vincacontaining compound .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Endometrial</keyword>
	<keyword>Phase II</keyword>
	<keyword>EC145</keyword>
	<keyword>EC20</keyword>
</DOC>